Guardant Health News Update

Listing Websites about Guardant Health News Update

Filter Type:

Guardant Health, Inc. - Guardant Health Announces Preliminary …

(3 days ago) WebFull year revenue growth of 25% driven by clinical volume growth of 39% Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023. Full year 2023 preliminary unaudited financial results For the twelve-month period …

https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Announces-Preliminary-Fourth-Quarterand-Full-Year-2023-Results/default.aspx

Category:  Health Show Health

Guardant Health Announces $90.7 Million Registered Direct …

(6 days ago) WebPALO ALTO, Calif., December 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with

https://finance.yahoo.com/news/guardant-health-announces-90-7-140000054.html

Category:  Health Show Health

Guardant Health Reports Fourth Quarter and Full Year 2022 …

(6 days ago) WebQ4 clinical and biopharma volumes up 41% and 24% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended …

https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-2023-Outlook/default.aspx

Category:  Cancer Show Health

Guardant Health, Inc. - Guardant Health to present 17 scientific

(3 days ago) WebNew research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from …

https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-to-present-17-scientific-abstracts-highlighting-contribution-of-its-blood-tests-and-real-world-data-to-advances-in-precision-oncology-and-cancer-screening-at-2023-ASCO-annual-meeting/default.aspx

Category:  Health Show Health

Guardant Health Announces Preliminary Fourth Quarter and Full

(1 days ago) WebFull year 2022 preliminary unaudited financial results. For the twelve-month period ended December 31, 2022, as compared to the same period of 2021: Revenue of between $447 million and $450

https://www.nasdaq.com/press-release/guardant-health-announces-preliminary-fourth-quarter-and-full-year-2022-results-2023

Category:  Health Show Health

Guardant Health to present real-world data supporting …

(5 days ago) WebThe forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward

https://www.businesswire.com/news/home/20240516838593/en/Guardant-Health-to-present-real-world-data-supporting-performance-of-Shield%E2%84%A2-blood-test-for-colorectal-cancer-screening-at-2024-Digestive-Disease-Week

Category:  Health Show Health

Guardant Health applauds proposed FY2024 budget increases and …

(4 days ago) WebPALO ALTO, Calif., March 10, 2023 – Guardant Health, Inc., alongside partners from across the advocacy community, industry and public sector, today participated in the White House’s Colorectal Cancer Forum to discuss concrete ways to advance the Biden-Harris Administration’s Cancer Moonshot goals.Reducing the death rate from …

https://guardanthealth.com/2023/03/11/guardant-health-applauds-proposed-fy2024-budget-increases-and-pledges-support-for-the-biden-harris-administration-moonshot-goal-to-end-cancer-as-we-know-it/

Category:  Cancer Show Health

Guardant Health Provides Update on COBRA Study, Restates …

(6 days ago) WebGuardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced stage cancer patients, and

https://www.businesswire.com/news/home/20230901319507/en/Guardant-Health-Provides-Update-on-COBRA-Study-Restates-Confidence-in-MRD-Test/

Category:  Cancer Show Health

Guardant Health Announces ECLIPSE Study Update Call on May 9, …

(7 days ago) WebGuardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer, and Guardant

https://www.businesswire.com/news/home/20230504006138/en/

Category:  Cancer Show Health

Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript

(6 days ago) Web146.63K Follower s. Guardant Health, Inc. ( NASDAQ: GH) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET. Company Participants. Helmy Eltoukhy - Chairman & Co-Chief Executive Officer

https://seekingalpha.com/article/4691776-guardant-health-inc-gh-q1-2024-earnings-call-transcript

Category:  Health Show Health

Guardant Health Inc (GH) Stock Price & News - Google Finance

(6 days ago) WebGet the latest Guardant Health Inc (GH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

https://www.google.com/finance/quote/GH:NASDAQ

Category:  Health Show Health

Guardant Health Announces Preliminary Fourth Quarter and Full …

(Just Now) WebPALO ALTO, Calif., January 08, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended

https://finance.yahoo.com/news/guardant-health-announces-preliminary-fourth-140000079.html

Category:  Health Show Health

Cancer Test Focused Guardant Health Stock Falls On FDA AdCom …

(6 days ago) WebGuardant Health surpasses Q4 2023 revenue expectations, reporting $155.1 million. Precision oncology revenue is up 25% to $142.2 million. Adjusted EPS loss beats consensus. Update on Shield CRC

https://markets.businessinsider.com/news/stocks/cancer-test-focused-guardant-health-stock-falls-on-fda-adcom-update-for-colorectal-test-1033098815

Category:  Health Show Health

Guardant Health Reports Third Quarter 2022 Financial Results

(5 days ago) WebQ3 clinical and biopharma volumes up 42% and 40% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, …

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Reports-Third-Quarter-2022-Financial-Results/default.aspx

Category:  Cancer Show Health

Guardant Health to present real-world data supporting - BioSpace

(2 days ago) WebGuardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New …

https://www.biospace.com/article/releases/guardant-health-to-present-real-world-data-supporting-performance-of-shield-blood-test-for-colorectal-cancer-screening-at-2024-digestive-disease-week/

Category:  Health Show Health

Home - GuardantHealth

(Just Now) WebRead the latest news, announcements, and stories from Guardant Health. Newsroom; Press Releases; Stories and Perspectives; Media Resources; Guardant Health is hiring bright minds in diverse fields to solve some of the most profound challenges in human health today. Learn more. 3100 Hanover Street Palo Alto, CA 94304.

https://en.guardanthealth.com/

Category:  Health Show Health

Press Releases - GuardantHealth

(1 days ago) WebNEWS. Press Releases. Featured Press Releases. May 9th, 2024. Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening Read More. All Press Releases. 2024 2023 2022 …

https://guardanthealth.com/newsroom/press-releases/

Category:  Cancer Show Health

Guardant Health to present real-world data supporting …

(9 days ago) WebGuardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New …

https://markets.financialcontent.com/stocks/article/bizwire-2024-5-16-guardant-health-to-present-real-world-data-supporting-performance-of-shield-blood-test-for-colorectal-cancer-screening-at-2024-digestive-disease-week

Category:  Health Show Health

Guardant Health, Inc. (GH) Stock Price, Quote, News & Analysis

(9 days ago) WebGuardant Health stock climbs following Piper Sandler upgrade SA News Wed, Sep. 27, 2023 Guardant Health Non-GAAP EPS of -$0.82 beats by $0.11, revenue of $137.2M beats by $7.78M

https://seekingalpha.com/symbol/GH/news

Category:  Health Show Health

Guardant Health stock slides, Exact Sciences gains amid FDA …

(3 days ago) WebGuardant Health (GH) shares slid 5% while rival Exact Sciences (EXAS) stock rose 3% the day after Guardant issued an update on its colorectal cancer blood test. Read more here.

https://seekingalpha.com/news/4048569-guardant-health-stock-slides-exact-sciences-gains-amid-fda-update

Category:  Cancer Show Health

Guardant Health, Inc. - Guardant Health Announces Shield™ Blood …

(Just Now) WebHighly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in validation studies Guardant Health, Inc. (Nasdaq: …

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Announces-Shield-Blood-Test-Available-in-US-to-Detect-Early-Signs-of-Colorectal-Cancer-in-Average-Risk-Adults/default.aspx

Category:  Cancer Show Health

2024-05-17 NDAQ:GH Press Release Guardant Health Inc

(2 days ago) WebGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock

https://stockhouse.com/news/press-releases/2024/05/17/guardant-health-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4

Category:  Health Show Health

Guardant Health, Inc. - Press Releases

(4 days ago) WebAt Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. News: Events & Presentations: Quarterly Reports: Annual Reports: SEC Filings: End of Day Stock Quote

https://investors.guardanthealth.com/press-releases/default.aspx

Category:  Health Show Health

Filter Type: